|
Memórias do Instituto Oswaldo Cruz
Fundação Oswaldo Cruz, Fiocruz
ISSN: 1678-8060 EISSN: 1678-8060
Vol. 90, Num. 2, 1995, pp. 255-256
|
Memorias Instituto Oswaldo Cruz, Vol. 90(2):255-256
mar./apr. 1995
Vaccination Against Schistosomiasis and Fascioliasis with the
New Recombinant Antigen Sm14: Potential Basis of a Multi-
Valent Anti-Helminth Vaccine?
Miriam Tendler, Monica Magno Vilar, Cristiana Alves Brito*,
Nicolau Maues da Serra Freire***, Naftale Katz*, Andrew
Simpson*/**
Laboratorio de Esquistossomose Experimental, Departamento de
Helmintologia, Instituto Oswaldo Cruz, Av. Brasil 4365, 21045-
900 Rio de Janeiro, RJ, Brasil *Laboratorio de Biologia
Molecular, **Laboratorio de Esquistossomose, Centro de
Pesquisas Rene Rachou - FIOCRUZ, Av. Augusto de Lima 1715,
30190-002 Belo Horizonte, MG, Brasil, *** Universidade Federal
Rural do Rio de Janeiro, RJ, Brasil
Code Number:OC95050
Size of Files:
Text: 9K
No associated graphics files
Molecular cloning of components of protective antigenic
preparations have suggested that related parasite fatty acid
binding proteins could form the basis of the well documented
protective, immune cross reactivity between the parasitic
trematode worms Fasciola hepatica and Schistosoma mansoni. We
have now confirmed the cross protective potential of parasite
fatty acid binding proteins and suggest that it may be
possible to produce a single vaccine that would be effective
against at least two parasites, F. hepatica and S. mansoni of
veterinary and human importance respectively.
Key words: schistosomiasis - fascioliasis - vaccines - fatty
acid binding protein (FABP)
Protective vaccination of Swiss outbred mice and rabbits with
a soluble extract of adult Schistosoma mansoni (SE)
resulted in 70 and 90% protection respectively, against
cercarial challenge as previously reported (Tendler et al.
1986, 1991). One of the components of SE has been identified
by gene cloning and sequencing as Sm14, a soluble lipid
binding protein (Moser et al. 1991).
A recombinant form of the S. mansoni, fatty acid
binding protein (FABP) rSm14 was produced (as a fusion protein
with the 260 amino acids of the bacteriophage T7 major capsid
protein under the control of the T7 gene 10 promoter) and used
for experimental vaccination in outbred animals.
Protective activity of rSm14 was first assessed in NZ rabbits
immunized and challenged with S. mansoni cercariae.
The adult worm burdens in these animals was compared with
positive controls vaccinated with SE, the saline extract
within which Sm14 was originally identified (Moser et al.
1991) and non-vaccinated negative controls.
The results demonstrated that the recombinant molecule
stimulated an extremely high level of protective immunity
close to that stimulated by complete SE.
More extensive analysis of the protective activity of rSm14
was carried out in four large, independent experiments in
Swiss mice. In all cases a high level of protection was
achieved by vaccinating with rSm-14 which ranged from 50.6 to
65.7% with Freund s Complete Adjuvant and from 51.4 to 67.9%
without adjuvant indicating that the inclusion of adjuvant is
not necessary for the stimulation of protective immunity.
Furthermore, as shown with rabbits, vaccination with rSm14
stimulated levels of protection that were not significantly
different from those achieved with SE which was 53.9% without
adjuvant and from 56.7 to 72.1% with adjuvant. Vaccination
with the T7 capsid protein alone did not stimulate any
measurable protection. Analysis of the distribution of worm
burdens among the animals in the four experiments demonstrated
that following vaccination with rSm14, up to 66% of the
animals harboured 10 or fewer worms in contrast to control
groups where the majority of animals had between 21 and 30
worms and where none had less than 11 worms.
Western blotting studies showed that rSm14 was specifically
and strongly recognized by antibodies from mice and rabbits
infected with S. mansoni as well as individuals from
endemic areas. Furthermore, anti-Sm14 antibodies produced by
immunizing New Zealand with rSm14 in the presence of Freund s
Complete Adjuvant, strongly labeled sections of adult S.
mansoni worms and reacted with a 14kDa molecule in Western
blots. However, these antibodies did not label any cell of
normal rabbit tissues including brain, heart, skeletal muscle,
small intestine, pancreas, kidney, liver spleen, thymus or
testis as assessed immunocytochemically.
In summary, rSm14 protected outbred Swiss mice and NZ rabbits
by up to 67 and 89% respectively, against challenge with S.
mansoni cercariae in the absence of adjuvant and without
provoking any observable auto-imune response.
Hillyer and co-workers have isolated a low molecular weight
Fasciola hepatica antigen fraction, that
protects against both S. mansoni and F. hepatica
infection in experimental animals (Hillyer 1984, 1985). An
active component of the protective fraction was putatively
identified by molecular cloning to be an antigen with homology
to the S. mansoni fatty acid binding protein (Sm14) and
termed Fh15 (Rodriguez-Perez et al. 1992). The coincidence of
these results suggested that the pair of similar parasite
proteins identified could provide a molecular basis for the
observed immune cross reaction between the two parasites. By
constructing molecular models of the two parasite proteins,
based on the known crystal structures of homologous mammalian
proteins, it was observed that both molecules adopt the same
basic three dimensional structure as mammalian fatty acid
binding proteins which consists of a barrel shaped molecule
formed by ten anti-parallel B-pleated strands joined by short
loops. Nevertheless, detailed examination revealed the likely
presence of cross reactive, discontinuous epitopes principally
derived from amino acids in the C-terminal portions of the
molecules.
To test the protective potential of rSm14 against F.
hepatica, Swiss mice immunized with rSm14 were orally
challenged with F. hepatica metacercariae in two
independent experiments. In both experiments detailed
histopathological examination revealed 100% protection against
parasite maturation and liver damage. The livers of all
animals in each experiment showed that in all non-vaccinated
animals complete parasite development and migration had
occurred as indicated by extensive damage to the hepatic
parenchyma and destruction of the hepatic lobes. In none of
the vaccinated animals were parasites of any developmental
stage observed nor were any intraperenchymal hepatic lesions
indicative of successful parasite maturation found.
Nevertheless, capsular cicatricial lesions were seen in all
vaccinated mice indicating that immature parasites had
successfully migrated to the liver but had not developed
further.
We were thus able to show that a recombinant fusion protein
containing the complete Sm14 polypeptide can stimulate a
potent protective response against both S. mansoni and
F. hepatica infection. The data suggest that Sm14 could
form the basis of a single vaccine effective against both
parasites. Such a multi-valent vaccine, aimed primarily for
veterinary use against an economically important disease such
as fascioliasis, may represent the most feasible route for
producing a vaccine for human use against schistosomiasis
which is endemic in developing countries.
REFERENCES
Hillyer GV 1984. Immunity schistosomes using heterologous
trematode antigens - A review. Vet Parasitol 14: 263-
283.
Hillyer GV 1985. Induction of immunity in mice to Fasciola
hepatica with Fasciola/Schistosome cross-reactive defined
immunity antigen. Am J Trop Med Hyg 34: 1127-
1131.
Moser D, Tendler M, Griffiths G, Klinkert MQ 1991. A 14-kDa
Schistosoma mansoni polypeptide is homologous to
a gene family of fatty acid binding proteins. J Biol Chem
266: 8447-8454.
Rodrigues-Perez J, Rodrigues-Medina JR, Garcia-Blanca MA,
Hillyer GV 1992. Fasciola hepatica: Molecular cloning,
nucleotide, sequence and expression of a gene encoding a
polypeptide homologous to a Schistosoma mansoni fatty
acid-binding protein. J Exp Parasitol 74: 400-407.
Tendler M, Pinto RM, Lima AO, Gebara G, Katz N 1986.
Schistosoma mansoni: Vaccination with adult worm
antigen. Int J for Parasitol 16: 347-352.
Tendler M, Pinto RM, Lima AO, Savino W, Katz N 1991.
Vaccination in murine schistosomioasis with adult worm-derived
antigens: Variables influencing protection in outbred mice.
Int J for Parasitol 21: 299-306.
Copyright 1995 Fundacao Oswaldo Cruz (Fiocruz)
|